PER-001 demonstrated a favorable safety and tolerability profile in diabetic retinopathy and glaucoma SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical ...
Studies show that GLP-1 receptor agonists have significant potential for treating glaucoma, diabetic retinopathy and other ...
LOS ANGELES, May 3, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of ...
A review published in BMC Ophthalmology has found that GLP-1 receptor agonists may help protect against ocular hypertension, glaucoma, late-stage diabetic retinopathy, and dry age-related ...
Eye care should not begin only when vision becomes blurry. The eyes change through childhood, school years, adulthood, and older age, and each stage brings different risks. Children need healthy ...
Please provide your email address to receive an email when new articles are posted on . GLP-1RA use was associated with a 19% reduction in risk for glaucoma in patients with type 2 diabetes. Long-term ...
If a person has diabetes, Medicare covers one annual eye exam for diabetic retinopathy. This exam must be performed by a doctor or healthcare professional who is legally allowed to conduct it in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results